The ageing process in animals and humans is thought to be accompanied by a gradual impairment of corticosteroid receptor function, which is reflected by increased pituitary-adrenocortical hormone secretion at baseline and a number of aberrant neuroendocrine function test results. The latter include the ACTH and corticosteroid responses to a combined dexamethasone (DEX)/corticotropinreleasing hormone (CRH) challenge. The excessive hormonal response to this test among aged individuals has been taken as indirect evidence of enhanced endogenous arginine vasopressin (AVP) release, which -together with peripherally administered CRH -is capable of overriding DEX-induced ACTH suppression. The current study was designed to explore the role of endogenous AVP in mediating excessive hypothalamic-pituitaryadrenocortical (HPA) activity in ageing. The combined DEX/CRH test was administered to aged (22-24 months old) Wistar rats and the effect of the AVP type 1 (V1) receptor antagonist, d(CH 2 ) 5 Tyr(Me)AVP, on ACTH release was studied. Infusion of the V1 receptor antagonist after DEX pretreatment and before CRH administration prevented the CRH-induced rise in ACTH secretion in comparison with vehicle-treated aged rats (area under the concentration-time curve: 699 479 versus 2896 759; P<0·01). This difference was absent in young (3 months old) control rats.
Introduction
Increased activity of the hypothalamic-pituitaryadrenocortical (HPA) system is a frequent concomitant of ageing. This led to the hypothesis that the neuroendocrine changes seen are causally involved in the development of both age-associated cognitive decline and stress-related psychiatric disorders, such as depression (for reviews see Holsboer & Barden 1996 , Lupien & McEwen 1997 . It has been postulated that these age-or disease-associated changes are induced by a synergistic action of corticotropin-releasing hormone (CRH) and arginine vasopressin (AVP) at pituitary corticotropic cells (von Bardeleben et al. 1985 , von Bardeleben & Holsboer 1991 , but only indirect evidence exists so far for a functional synergism between CRH and AVP as a crucial mechanism underlying excessive adrenocorticotropin (ACTH) and corticosteroid release in dexamethasone (DEX)-pretreated aged humans and animals (von Bardeleben & Holsboer 1991 , Hatzinger et al. 1996 .
The current study was designed to elucidate the role of endogenous AVP in age-related alterations of the HPA system in rats. The combined DEX/CRH challenge was used as a paradigm because this test is an extremely sensitive measure for changes in the HPA system regulation in both humans and rats (Heuser et al. 1994a , Hatzinger et al. 1996 . The mechanisms underlying the excessive secretion of ACTH and corticosteroids in aged individuals are believed to involve impaired corticosteroid receptor function in the limbic system (Sapolsky et al. 1986 , Reul et al. 1991 , Rothuizen et al. 1993 . Since DEX, which suppresses ACTH, is rapidly exported from the brain by a transporter system of the blood-brain barrier (Schinkel et al. 1995) , it has very limited access to brain tissues and, thus, should rather exert a pituitary than a central site of action in its suppressive effect on pituitaryadrenal activity (de Kloet et al. 1975 , Meijer et al. 1998 . Thus, at a functional level, a low dose of DEX poorly substitutes for depletion of the endogenous corticosteroid receptor ligands from the brain and, therefore, in this tissue, may cause a condition resembling that of adrenalectomy or corticosteroid receptor antagonism (van Haarst et al. 1996) . In response to this intervention, an enhanced release of corticotropic secretagogues from the hypothalamus, including CRH and AVP, occurs. Hence, in the context of the combined DEX/CRH test, this would result in inadequate suppression of ACTH and cortisol/ corticosterone by DEX and, through the joint action of increased endogenous AVP and exogenous CRH, in excessive ACTH and corticosteroid secretion (Antoni 1986 , von Bardeleben & Holsboer 1989 , Heuser et al. 1994b , Hatzinger et al. 1996 .
To elaborate this functional role of endogenous AVP we administered systemically an AVP receptor (V1) antagonist, expecting that this intervention would abolish the DEX/CRH-induced pituitary-adrenocortical activation in aged rats. The antagonist used is able to distinguish between V1 and V2 AVP receptors, but not between the V1 receptor subtypes (Thibonnier et al. 1997) . AVP that is released into portal blood vessels (Herman et al. 1989 ) may originate not only from parvocellular, but also from magnocellular neurons of the hypothalamic paraventricular nucleus (PVN) (Holmes et al. 1986 , Antoni et al. 1990 , Wotjak et al. 1996 . To define the brain area from which AVP acting at the pituitary of aged rats is derived, and to investigate possible age-associated alterations in the responsiveness of paraventricular CRH and AVP neurons to the inhibitory action of DEX, we used in situ hybridization of CRH mRNA and AVP mRNA in DEXpretreated aged and young animals. Preliminary results have been presented in abstract form (Hatzinger et al. 1997) .
Materials and Methods

Animals
The animal studies were performed according to the Bavarian law (Germany) for the care and use of laboratory animals. Experiments were carried out on young adult (379 10 g body weight, 3 months old, n=19) and aged (672 18 g body weight, 22-24 months old, n=28) male Wistar rats (Charles River, Sulzfeld, Germany). Rats were housed under standard laboratory conditions with a 12 h light:12 h darkness cycle (lights on at 0600 h; 22 1 C, 60% humidity); pelleted food and water were available ad libitum. Two weeks before the experiment, all rats were allowed to adapt in the laboratory, housed singly, and were handled daily to reduce non-specific stress during the experiments.
Surgery and blood sampling
Five days before testing, the jugular vein was chronically catheterized under halothane anesthesia for subsequent drug infusion and blood sampling. The catheter was exteriorized on the neck of the animal, filled with sterile saline (0·9% NaCl) containing gentamicin (30 000 IU/ml; Centravet, Bad Bentheim, Germany), closed with a stylet and flushed once after 3 days.
On the day of the experiment at 0900 h, the jugular vein catheter was connected via 50 cm PE-50 tubing to a 1 ml sterile plastic syringe filled with heparinized saline (30 IU/ml). At selected time-points, blood samples (0·2 ml) were collected on ice in EDTA-coated tubes containing aprotinin (10 µl/tube; Bayer AG, Leverkusen, Germany) and replaced by the same volume of sterile saline (0·9% NaCl). After centrifugation (4 C, 5000 r.p.m., 5 min), the plasma was stored at 20 C (corticosterone) and 80 C (ACTH) respectively, until assay.
DEX/CRH test in vehicle-or V1 antagonist-treated young and aged rats
The DEX/CRH test was performed in young (n=19) and aged (n=28) rats as previously described (Hatzinger et al. 1996) . In brief, DEX (30 µg/kg, dissolved in 0·9% saline; 0·5 ml/kg; Merck, Darmstadt, Germany) was administered i.v. during the diurnal trough of the rats' HPA system at 1200 h. For monitoring the effects of DEX treatment on basal plasma concentrations of ACTH and corticosterone during the diurnal acrophase, three 0·2 ml blood samples were collected at 1800, 1900 and 1930 h. At 1945 h, either vehicle (0·9% saline, 0·5 ml/kg; 9 young and 13 aged rats) or the AVP V1 receptor antagonist d(CH 2 ) 5 Tyr(Me)AVP (10 µg/kg dissolved in 0·9% sterile saline, 0·5 ml/kg; Dr M Manning, Toledo, OH, USA; 10 young and 15 aged rats) was injected i.v. An additional blood sample was taken at 2000 h, and thereafter CRH (50 ng/kg, 0·5 ml/kg) was injected. To assess the CRHstimulated ACTH and corticosterone levels, further blood samples were taken at 2010, 2030, 2050 and 2110 h.
The next morning, 2 ml blood was withdrawn from the jugular vein for measurement of general laboratory parameters, including hematology (leukocytes, hemoglobin, red blood cell (RBC) count, volume of packed RBC, platelets), blood chemistry (sodium, potassium, chlorine, calcium, phosphate, creatinine, liver enzymes, amylase), and thyroid function (thyroid-stimulating hormone). Afterwards, the animals were killed by decapitation under light halothane anesthesia and the brains of four young and six aged vehicle-treated rats were quickly removed, frozen in prechilled n-methylbutane on dry ice and stored at 80 C for subsequent in situ hybridization histochemistry. In all animals, the pituitary, adrenals and internal organs were visually examined to exclude from statistical analysis animals with pituitary or adrenal tumours or with other internal diseases.
Hormone assays
For estimation of plasma ACTH and corticosterone concentrations, commercially available radioimmunoassay kits (ICN, Costa Mesa, CA, USA) were used. The intra-and interassay coefficients of variation were below 7 and 10% respectively.
Recordings of blood pressure and heart rate in young and aged rats
To monitor the effects on the cardiovascular system of the V1 antagonist used, the femoral vein and artery of urethane-anesthetized young (n=7, 3 months old) and aged (n=10, 18 months old) Wistar rats (Charles River, Montreal, Quebec, Canada) were catheterized for drug infusion and blood pressure recording respectively. Sixty minutes after surgery, basal blood pressure and heart rate were recorded (Statham pressure transducer) for at least 30 min. Then vehicle (0·5 ml/kg, 0·9% saline) was administered i.v. to all rats. After another 30 min, the V1 antagonist was infused (10 µg/kg, 0·5 ml/kg) and recordings were continued for 45-60 min.
In situ hybridization histochemistry
In situ hybridization histochemistry was performed essentially as previously described (Wisden & Morris 1994) . Briefly, consecutive frozen cryostat sections of the rat hypothalamus (14 µm) were alternately mounted on poly--lysine-coated slides for subsequent hybridization of either AVP or CRH mRNA. Sections were lightly fixed in ice-cold 4% paraformaldehyde, dehydrated and stored in 96% ethanol at 4 C. To detect both AVP and CRH mRNAs, two synthetic oligonucleotides were used: 5 -CAT GGC GAG CAT AGG TGG GCA CTG CGT GCA GC-3 (complementary to the cDNA sequence of AVP, corresponding to nucleotides 229-260; Ivell & Richter 1984) and 5 -CAG TTT CCT GTT GCT GTG AGC TTG CTG AGC TAA CTG CTC TGC CCT-3 (cDNA of CRH, nucleotides 496-543; Jingami et al. 1985) . According to a computer database search, neither oligonucleotide showed internal complementarity or resembled any other known sequence. Probes were 3 -end-labeled with [ -35 S]dATP (>1000 Ci/mmol; Amersham International plc. Amersham, Bucks, UK) by terminal deoxynucleotidyl transferase (BoehringerMannheim, Mannheim, Germany). Sections were then hybridized with the labeled probes in hybridization buffer (50% formamide, 4 SSC, 10% dextran sulphate, 5 Denhardt's, acid-alkali-cleaved salmon sperm DNA; Wisden et al. 1994) at 42 C for 20 h. After hybridization, slides were washed in 1 SSC at 55 C for 30 min, rinsed in 1 SSC, and 0·1 SSC, dehydrated through graded alcohols and dried at room temperature. Slides were apposed to X-ray film (Kodak Biomax) for 7-10 days, thereafter dipped in photographic emulsion (diluted 1:1 with water; Kodak, NTB-2) and exposed for 6 weeks. After developing, sections were stained with hematoxylineosin and coverslipped.
To control for specificity of the oligonucleotide binding, some sections were preincubated with a 50-fold excess of the cold oligonucleotides before adding the radioactive labeled probes. Under these conditions, no signals were registered within the respective nuclei.
For evaluation of the hybridization signals, sections of the same level of the PVN were chosen according to the autoradiograms, the brain atlas of Paxinos & Watson (1986) , and histological criteria (prominent part of magnocellular and parvocellular neurons respectively). For objective evaluation, the images of at least three sections per animal were grabbed by a computer-assisted image analyzer (Optimas-Bioscan) fitted with a Zeiss Axioplan microscope and a Sony CCD camera. The images were overlapped with predefined masks, which enclosed either the magnocellular or the parvocellular part of the PVN (according to Kiss 1988 , Kiss et al. 1991 . Subsequently, the number of positively labeled neurons (number of silver grains over the cell at least twice as high as the background) and the number of silver grains per positively labeled cell were counted by a person blind to the sections' coding. The number of silver grains was counted for one to, if possible, six positively labeled neurons randomly chosen from each image.
Statistical analysis
Results are reported as means ... After CRH administration, ACTH and corticosterone responses were computed as the area under the concentration-time curve (AUC, arbitrary units) corrected for basal concentration (averaged plasma concentration of ACTH and corticosterone, respectively, between 1800 and 1930 h) using trapezoidal integration according to Forsythe et al. (1969) . The maximal increase of ACTH and corticosterone levels after CRH administration (time between 2000 and 2110 h) is reported as delta value (maximal concentration corrected for basal concentration). Additionally, the ratios of the AUCs for ACTH and corticosterone were calculated as a crude estimate of adrenal responsiveness to ACTH (pituitary-adrenal ratio).
To evaluate the in situ hybridization, the averaged number of positively labeled neurons per animal and the mean number of silver grains per cell and animal were calculated.
Statistical analysis was performed with a statistical software package (GB-Stat version 5·4; Dynamic Microsystems, Silver Spring, MD, USA). Statistical significance was determined by one-way ANOVA for repeated measurements followed by Fisher's least significant difference (LSD) protected t-test (treatment response), two-way ANOVA for repeated measurements (age treatment response, and for comparisons of basal, delta and AUC values) followed by Fisher's LSD protected t-test, or the Mann-Whitney U test (for comparisons of the number of positively labeled cells and silver grains). Statistical significance was accepted if P<0·05.
Results
Animals
Six of the aged animals had to be excluded from statistical analysis due to tumours found on visual examination (liver, kidney, testis, pituitary or skin). In the remaining animals (aged: n=22; young: n=19), adrenal wet weight was significantly higher in the aged rats than in the young rats (76 4·0 mg vs 57 4·0 mg; P<0·01), whereas there was no difference in pituitary wet weight (aged: 21 3·0 vs young: 16 2·0 mg; P=0·35). However, if these values were corrected for body weight, a significant decrease of adrenal weight/kg body weight was demonstrated in the aged compared with the young animals (113 5 vs 52 10 mg/kg; P<0·01). Pituitary weight/kg body weight was not changed significantly in aged rats (aged: 34 5 vs young: 43 3 mg/kg; P=0·138). Routine laboratory investigations did not reveal any differences between young and aged animals.
DEX/CRH test in young and aged rats treated with vehicle
After DEX treatment the release of ACTH in response to CRH was significantly higher in the aged rats than in the young rats (two-way ANOVA, age time: P=0·027), which was also reflected by significantly higher AUC values (P<0·05) (Figs 1 and 2, Table 1) . Similarly, the maximal rise of the corticosterone concentration in plasma after CRH stimulation was significantly higher in the aged than in the young rats (two-way ANOVA, age time: P=0·0002), with significantly higher values at both 2030 and 2110 h (Figs 1 and 2) , although the differences in the AUC between the two groups of rats were not statistically significant (P=0·64).
Although the pituitary-adrenal ratio tended to be higher in the aged animals (0·90 0·37) than in the young animals (0·53 0·12; P=0·94), this difference failed to reach statistical significance, indicating that the global adrenal responsiveness was not significantly altered in the aged rats.
DEX/CRH test in aged rats treated with vehicle or V1 antagonist
After DEX treatment, basal ACTH and corticosterone levels between 1800 and 1930 h did not differ significantly between the groups of aged rats treated subsequently with either vehicle or the V1 antagonist (Fig. 1, Table 1 ). Administration of vehicle or the V1 antagonist had no immediate effect (first 15 min) on ACTH or corticosterone secretion (Fig. 1) . However, application of the V1 antagonist abolished or reduced the CRH-stimulated increase in both ACTH and corticosterone secretion seen in the vehicle-treated aged animals (two-way ANOVA, time treatment: P<0·0007 and P<0·004 respectively). This effect was also reflected by significantly lower delta values for ACTH (P<0·05), and significantly lower AUC values for both ACTH (P<0·01) and corticosterone (P<0·05) ( Table 1) .
DEX/CRH test in young rats treated with vehicle or V1 antagonist
After DEX treatment, basal ACTH and corticosterone levels between 1800 and 1930 h did not differ significantly between the groups of young rats treated subsequently with either vehicle or the V1 antagonist (P=0·51; Fig. 2 , Table 1 ). Administration of vehicle or the V1 antagonist per se had no immediate effect (first 15 min) on ACTH or corticosterone secretion (Fig. 2) . Furthermore, the #P<0·01 vs corresponding values in V1 antagonist-treated rats (two-way ANOVA, treatment time, ACTH: P=0·0007, corticosterone: P=0·0037 followed by Fisher's LSD protected t-test). *P<0·01 vs corresponding baseline levels (two-way ANOVA for repeated measurements, factor time, ACTH: P=0·0002, corticosterone: P<0·0001 followed by Fisher's LSD protected t-test).
CRH-stimulated secretion of ACTH and corticosterone did not differ between the vehicle-and the V1 antagonisttreated young rats (two-way ANOVA, factor time treatment: P=0·74 and P=0·08 respectively; Fig. 2 , Table  1 ).
Cardiovascular effects of V1 antagonist administration in young and aged rats
Basal systolic (aged: 93·0 5·2 vs young: 113 10·3 mmHg) and diastolic blood pressure (59·7 3·2 vs 69·7 6·7 mmHg) did not differ significantly between the groups of urethane-anesthetized rats. Administration of the V1 antagonist affected systolic and diastolic blood pressure to a similar extent in the two groups of rats within 5-10 min after i.v. infusion, with a maximal response after 10 min (delta systolic, aged: 12 2·3, young: 19 5·3 mmHg; delta diastolic, aged: 7·5 1·7, young: -12·0 3·6 mmHg; two-way ANOVA, factor time: P<0·01 both) and no significant difference between groups. Similarly, infusion of the V1 antagonist affected the heart rate to a similar extent in the two groups (aged: from 278 15·7 to 288 18·3; young: from 342 21·3 to 351 23·4 beats/min; factor time: P<0·0002) with no significant difference between groups.
Expression of AVP and CRH mRNAs within the PVN of young and aged rats
The number of magnocellular neurons of the PVN synthesizing AVP did not differ significantly between the young adult and aged animals (Fig. 3A, P=0·52) . The number of silver grains per magnocellular neuron tended to be higher, but also showed greater variability in aged than in young animals (Fig. 3B, P=0·14) . In contrast, the number of parvocellular neurons positively labeled for AVP mRNA was significantly higher in aged rats (Fig. 3C, P=0·019) , whereas the number of silver grains per parvocellular neuron did not differ between the two groups of animals (Fig. 3D, P=0·29) (Fig. 4) . Values are means S.E.M. There were no significant differences between groups (two-way ANOVA, treatment time, ACTH: P=0·7371, corticosterone: P=0·0775). *P<0·05 and **P<0·01 vs corresponding baseline levels (two-way ANOVA for repeated measurements, factor time, both ACTH and corticosterone: P<0·0001 followed by Fisher's LSD protected t-test). Table 1 Basal (between 1800 and 1930 h), delta (peak value corrected for baseline) and AUC (area under the concentration-time curve corrected for baseline) values of ACTH and corticosterone in plasma during the combined DEX/CRH test in young adult and aged male Wistar rats treated with vehicle (VEH) or the AVP receptor 1 antagonist (V1). Values are means S.E.M.
Young rats
Aged rats Rats chronically implanted with a catheter in the jugular vein 5 days before testing were treated with DEX (30 g/kg) at 1200 h and basal blood samples were taken between 1800 and 1930 h. VEH or V1 antagonist (10 g/kg) was infused at 1945 h, before CRH (50 ng/kg) was administered at 2000 h. *P<0·05 and **P<0·01 vs VEH-treated aged rats; #P<0·05 vs VEH-treated young rats; †P<0·05 vs V1-treated young rats (two-way ANOVA followed by Fisher's LSD protected t-test).
With respect to CRH, the number of parvocellular neurons of the PVN positively labeled for CRH mRNA and the number of silver grains per parvocellular neuron were significantly higher in the aged animals ( Fig. 3E and F, P=0·019 and P=0·011 respectively).
Discussion
The current study has explored the origin and functional role of endogenous AVP in producing excessive release of ACTH and corticosteroids when CRH is administered to DEX-pretreated aged rats. When DEX was given during the diurnal trough (1200 h) of the rats' HPA system activity, CRH administered at 2000 h (when HPA activity is gradually declining) could override the suppressive effect of DEX on ACTH secretion in aged, but not young, Wistar rats, which is in accordance with our previous results (Hatzinger et al. 1996) . The major finding of the present study is that the ACTH increase can be abolished by peripheral administration of a V1 receptor antagonist; this is the first direct evidence that the enhanced activity of AVP-expressing neurons is functionally involved in age-dependent HPA hyperactivity.
Previous findings in aged human controls (Heuser et al. 1994b) , aged depressed patients (von Bardeleben & Holsboer 1991) and aged rats (Hatzinger et al. 1996 , Heroux et al. 1991 , Tizabi et al. 1992 , together with the equivalent pituitary-adrenal ratios in aged and young rats obtained in the present study provide indirect evidence for a hypothalamic rather than a pituitary or adrenocortical origin of age-related HPA dysregulation. A synergistic effect between CRH and AVP has been suggested by a large number of studies in which these neuropeptides were co-administered (Gillies et al. 1982 , von Bardeleben et al. 1985 , Antoni et al. 1990 . Moreover, as in chronic stress in rats (de Goeij et al. 1992 , Lightman et al. 1993 , an increased number of AVP-and CRH-expressing neurons has been found in human senescence (Hoogendijk et al. 1985 , Raadsheer et al. 1994 . The findings reported here of increased expression of CRH mRNA and AVP mRNA in the parvocellular part of the PVN in DEX-pretreated aged rats, together with our neuroendocrine results support the view that, in ageing, enhanced hypothalamic AVP activity may lead to increased functional action of AVP at corticotropic cells.
The reason why this phenomenon is observed in aged rats only is not yet clear, but, most likely, age-dependent changes in corticosteroid receptor-mediated signaling are involved. Glucocorticoids inhibit HPA system activity primarily via glucocorticoid receptors (GRs) located within the parvocellular part of the PVN and on anterior pituitary corticotropes and via a co-ordinated negative feedback action of mineralocorticoid receptors and GRs in the hippocampus (Reul & de Kloet 1985 , de Kloet et al. 1993 . There is compelling evidence that the function of hippocampal corticosteroid receptors gradually becomes impaired with increasing age (Reul et al. 1991 , van Eekelen et al. 1991 , Rothuizen et al. 1993 . Reduced corticosteroid capacity leading to insufficiently suppressed hypothalamic CRH and AVP gene expression is likely, as the transcriptional activity of both genes is highly sensitive to minor changes in circulating glucocorticoids (Davis et al. 1986 , Kovács et al. 1986 ). Importantly, neurons that either express AVP or CRH or co-express the two neuropeptides also express high levels of GRs (Fuxe et al. 1985 , Herman 1993 . The ligand-mediated activation of GRs would be sufficient to suppress AVP and CRH expression, provided that GR signaling is effective (Sawchenko 1987 , Knapp et al. 1995 . Thus, our data showing increased hypothalamic neuropeptide mRNA expression after DEX pretreatment are in line with the view of impaired corticosteroid receptor function in ageing.
In the aged rats studied here, enhanced AVP mRNA expression was restricted to parvocellular neurons. The contribution of magnocellular AVP to HPA activation is still a matter of debate, although there is increasing evidence that magnocellular neurons are capable of releasing AVP into portal blood vessels, either while passing through the median eminence or by short portal vessels from the posterior pituitary (Holmes et al. 1986 , Antoni et al. 1990 ). However, our finding suggests that, at least under the current experimental conditions, the age-related AVP enhancement is restricted to the parvocellular neurons.
In theory, the effect induced by the V1 receptor antagonist could have been contaminated because the synthetic drug might have caused stress-related changes via systemic cardiovascular actions. However, this seems rather unlikely because there were no age-related differences in the blood pressure or heart rate response to the synthetic peptide. Nevertheless, besides AVP, a possible involvement of oxytocin has to be considered. Recently, an in vitro study showed that oxytocin is able to trigger ACTH release from corticotropes via action at V1 receptors (Schlosser et al. 1994) . However, so far, the role of oxytocin in HPA system regulation is controversial (Fliers et al. 1985 , Silverman et al. 1990 , Neumann et al. 1999 .
In summary, we have demonstrated that the enhanced ACTH secretion following CRH in DEX-pretreated aged rats involves activation of V1 receptors, since the ACTH response can be abolished by co-administration of a V1 receptor antagonist. Furthermore, expression of AVP mRNA is increased in the parvocellular part of the PVN of DEX-pretreated aged rats. Thus, the resulting increased release of AVP into portal vessels would, together with exogenous CRH, mediate the escape of ACTH and corticosterone from DEX-induced HPA suppression. Circumstantial evidence supports the view that the primary cause of this abnormality may be due to corticosteroid receptor malfunctioning. In view of the clinical data derived from aged humans (Holsboer & Barden 1996) , these findings can probably be extrapolated to clinical conditions.
